Clinical trials
Pembrolizumab clinical trials
Below are recruiting pembrolizumab clinical trials, each written for real people, not researchers. We’re tracking 601 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06780111RecruitingPhase 1/Phase 2
Combination therapy study for advanced esophageal cancer
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06772623RecruitingPhase 1/Phase 2
Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
Phoenix, ArizonaAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Chandler, ArizonaAges 18 years+ - NCT06764875RecruitingPhase 3
New drug combo for HER2-positive stomach cancer
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
Anchorage, AlaskaAges 18 years+ - NCT06743126RecruitingPhase 3
IMA203 vs standard treatment for advanced skin cancer
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
Phoenix, ArizonaAges 18 years+ - NCT06745882RecruitingPhase 2
Pembrolizumab for Black Patients with Advanced Lung Cancer
This study tests if the drug pembrolizumab (Keytruda), alone or with chemotherapy, works well for Black patients with advanced non-small cell lung cancer (NSCLC) who haven't had treatment yet. The goal is to see real-world results in this group.
Tampa, FloridaAges 18 years+ - NCT06736379RecruitingPhase 1
Injected immune therapy for head and neck cancer
This trial tests an experimental treatment that is injected directly into the tumor to stimulate your immune system to fight the cancer. It is for people with head and neck cancer who have not been helped by prior treatments or who are scheduled for surgery.
Stanford, CaliforniaAges 18 years+ - NCT06731270RecruitingPhase 2
Diclofenac for advanced lung cancer on immunotherapy
This trial tests whether adding the anti-inflammatory drug diclofenac can help people with advanced non-small cell lung cancer whose tumors are growing while on a single immunotherapy drug. You must have been on immunotherapy for at least 12 weeks and have a growing tumor, but your doctor does not plan to change your treatment right away.
Atlanta, GeorgiaAges 18 years+ - NCT06725368RecruitingPhase 2
Chemo plus cetuximab after pembrolizumab for head and neck cancer
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Ars-LaquenexyAges 18 years+ - NCT06712316RecruitingPhase 2/Phase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
Birmingham, AlabamaAges 18 years+ - NCT06697301RecruitingPhase 2/Phase 3
New drug with pembrolizumab for advanced melanoma
This trial tests a new drug (EIK1001) combined with the standard immunotherapy pembrolizumab (Keytruda) for people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to see if adding EIK1001 is more effective than placebo plus pembrolizumab.
Chandler, ArizonaAges 18 years+ - NCT05394103RecruitingPhase 1/Phase 2
Testing a targeted pill for hard-to-treat solid tumors
This trial tests a new medicine (Q901) that targets a specific cell-control pathway to treat advanced cancers that have stopped responding to standard care. It’s mainly for people with certain solid tumor cancers, aiming to see whether the drug can shrink tumors or control disease.
Phoenix, ArizonaAges 18 years+ - NCT06657157Recruiting
Nerve side effects study for new bladder cancer treatment
This study watches for nerve problems in people getting enfortumab vedotin and pembrolizumab as their first treatment for advanced bladder cancer. It aims to understand how common these side effects are and how they affect patients.
Augsburg, BavariaAges 18 years+ - NCT06634875RecruitingPhase 2
Test of isunakinra alone or with pembrolizumab for colorectal cancer
This trial tests a new drug combination (isunakinra plus pembrolizumab) for people with a specific type of colorectal cancer (MSS, RAS-mutated) that has a high tumor mutational burden. It may help if other treatments have stopped working.
Los Angeles, CaliforniaAges 18 years+ - NCT06640283RecruitingPhase 2
Circulating tumor DNA monitoring for cervical and anal cancer
This trial uses a blood test to track tumor DNA in patients with HPV-related cervical or anal cancer. It aims to see if this test can detect early signs of recurrence after radiation therapy, helping guide follow-up care.
São PauloAges 18 years+ - NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT06600321RecruitingPhase 1
Study of ALN-BCAT for liver cancer
This trial tests a new drug called ALN-BCAT for people with advanced liver cancer (hepatocellular carcinoma) that has a specific genetic change. If you have already tried at least one treatment, this study may be an option for you.
Phoenix, ArizonaAges 18 years+ - NCT05879653RecruitingPhase 2
Pembrolizumab, drug EV, and radiation for bladder cancer
This Phase 2 study tests how well pembrolizumab and an antibody-drug medicine (EV) given with bladder radiation work for non-metastatic bladder cancer that is mostly urothelial. It may help some people control the cancer without it spreading to other organs.
Kobe, HyōgoAges 18 years+ - NCT06561685RecruitingPhase 1
Study of LY4050784 for Advanced Solid Tumors with SMARCA4 Changes
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
Santa Monica, CaliforniaAges 18 years+ - NCT06551142RecruitingPhase 1
Study of GSK5764227 for advanced solid tumors
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
Stanford, CaliforniaAges 18 years+ - NCT06549855Recruiting
PD-1 inhibitor plus progesterone for fertility preservation in MMRd endometrial cancer
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor) and progesterone hormone therapy to treat early-stage, MMR-deficient endometrial cancer while preserving fertility. It may help young women who want to keep the option to have children in the future.
Beijing, Beijing MunicipalityAges 18–45 - NCT06545331RecruitingPhase 1
A study of XB010 for advanced solid tumors
This trial tests an investigational drug called XB010 for people with solid tumors that have spread or cannot be removed by surgery. It aims to see if XB010 is safe and effective for several cancer types, including lung, breast, head and neck, and esophageal cancers.
Irvine, CaliforniaAges 18 years+ - NCT06545955RecruitingPhase 3
Gene therapy study for high-grade bladder cancer not responding to BCG
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
Tucson, ArizonaAges 18 years+ - NCT06543576RecruitingPhase 1/Phase 2
Radiation and drug therapy for stage IVB cervical cancer
This trial tests combining external and internal radiation with chemotherapy and immunotherapy for stage IVB cervical cancer that has not been treated before. The goal is to see if this approach can help shrink tumors and improve outcomes.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Pembrolizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pembrolizumab?
- Yes. Clin2 currently lists 601 recruiting pembrolizumab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pembrolizumab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pembrolizumab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.